摘要:目的:探讨磷脂酰肌醇蛋白-3(glypican-3,Gpc-3)和肝细胞石蜡抗原(hepatocyte paraffin antigen,HepPar-1)在原发性肝细胞肝癌(hepatocellular carcinoma,HCC)中的诊断价值及临床意义。方法:收集30例经病理诊断为HCC的肝组织标本,用免疫组化法染色,观察Gpc-3及HepPar-1在组织切片中的表达情况,对相关数据进行统计分析。同时分析患者的临床资料,采用χ2检验对Gpc-3及HepPar-1在HCC癌中的表达及其临床病理特征的关系进行研究。收集15例新鲜肝癌标本,采用RT-PCR法检测Gpc-3在HCC癌组织及癌旁组织的表达情况,观察癌及癌旁组织Gpc-3阳性率。结果:(1)免疫组化结果显示:Gpc-3在肝癌组织中的阳性率为83.33%(25/30),癌旁组织阳性率为23.33%(7/30),二者相比,差异有统计学意义(P<0.01);HepPar-1在癌组织中的阳性率为33.33%(10/30),癌旁组织阳性率为80%(24/30),二者相比,差异有统计学意义(P<0.05)。应用Kappa统计学方法分析Gpc-3和HepPar-1在癌组织的表达情况,结果实际测得疾病例数与预测例数一致性相当好(Kappa=0.813,P<0.05)。高分化HCC中Gpc-3表达阳性率为73.33%(11/15),中/低分化癌组织为93.33%(14/15),高分化与中/低分化病理分化程度之间的Gpc-3表达相比较,差异有统计学意义(P<0.05)。高分化HCC中HepPar-1表达阳性率为33.33%(5/15),中低分化癌组织为26.67%(4/15),HepPar-1在不同病理分化程度之间表达相比较,差异无统计学意义(P>0.05)。 Gpc-3阳性表达与性别、年龄、肿块直径、包膜是否完整、淋巴侵犯、门静脉癌栓、谷酰转肽酶(gamma-glutamyl transpeptidase,GGT)、总胆红素(total bilirubin,TBIL)无关(均 P>0.05),与分化程度、HBSAg、甲胎蛋白(α-fetoprotein,AFP)有关(P<0.05)。 HepPar-1阳性表达与性别、年龄、分化程度、肿块直径、包膜是否完整、门静脉癌栓、AFP、GGT、TBIL 无关(均P>0.05),与淋巴侵犯、HBSAg有关(P<0.05)。 Gpc-3和 HepPar-1在HCC中的表达无明显相关性(r=0.158,P>0.05);(2)RT-PCR法结果提示Gpc-3 mRNA在HCC组织中高表达,明显高于癌旁组织(P<0.01)。结论:(1)联合应用Gpc-3和HepPar-1在HCC中的表达,其实际测得疾病例数与预测例数有很好的一致性,准确率为93.75%,因此Gpc-3联合HepPar-1对HCC的诊断具有提高诊出率,减少漏诊率等优点;(2)Gpc-3阳性表达与病理分化程度、HBSAg、AFP有关;HepPar-1阳性表达与淋巴侵犯、HBSAg有关;(3)Gpc-3和HepPar-1在HCC中的表达无明显相关性。两者均可作为HCC的独立预测因素,而两者联合应用,具有较好的临床使用价值。%Objective: To discuss the diagnosis and the clinical significance of glypican-3(Gpc-3) and phosphatidylinositol and hepatocyte paraffin antigen-1(HepPar-1) in hepatocellular carcinoma. Methods: Immunohistochemical method was used in 30 tissue samples of hepatocellular carcinoma(HCC) to observe the Gpc-3 and HepPar-1 expression for statistical analysis. Collection with clinical data of 30 patients, with theχ2 testing the relation of Gpc-3 and HepPar-1 expression in HCC and its clinical pathological features. 15 cases of fresh liver cancer specimens by RT-PCR assay Gpc-3 in HCC tissues and adjacent tissues, the expression of observed cancer and adjacent tissues Gpc-3-positive rate. With 15 cases with fresh liver cancer specimens , the expression of Gpc-3 gene in HCC tissues and adjacent tissues was detected by RT-PCR, and observed the Gpc-3-positive rate . Results: ( 1 ) Immunohistochemical results showed that: the positive rate of Gpc-3 in hepatocellular carcinoma was 83.33%(25/30),the positive rate of adjacent tissues is 23.33%(7/30), respectively. There was a significant difference between the cancer tissues and adjacent tissues(P<0.01). The positive rate of HepPar-1 in hepatocellular carcinoma is 33.33%(10/30), adjacent tissues is 80%(24/30),to compared with each other,there was a significant difference(P<0.05). With Kappa statistical methods to analyze the expression of Gpc-3 combined with HepPar-1 in cancer tissue,the results of the consistency of the actual number of disease cases and prediction of the number of cases is quite good ( Kappa=0 . 813 , P<0.05). The positive expression rate of Gpc-3 in well-differentiated hepatocellular carcinoma is 73.33%(11/15), In poorly differentiated cancer tissue is 93.33%(14/15). It is obviously different between the pathological grade ( P<0 . 05 ) . The positive expression rate of HepPar-1 in well-differentiated hepatocellular carcinoma is 33.33%(5/15), In poorly differentiated cancer tissue is 26.67%(4/15). Between the pathological grade, there was no significant difference(P>0.05). The positive expression of Gpc-3 in hepatocellular carcinoma is no relationship with gender, age, tumor diameter, capsular integrality , lymph node involvement, tumor thrombus in the portal vein, GGT, TBIL(P>0.05), but with the degree of differentiation, HBSAg, and AFP(P<0.05). The positive expression of HepPar-1 is no relationship with gender, age, degree of differentiation, tumor diameter, capsular integrality, portal vein tumor thrombus,AFP,GGT,TBIL(P>0.05),but with lymphatic invasion, HBSAg ( P<0 . 05 ) . Gpc-3 and HepPar-1 expression in HCC had no correlation with each other. (2)Rt-PCR results suggest that,Gpc-3 in hepatocellular carcinoma tissues was significantly higher expression than the adjacent tissues(P<0.01). Conclusions:(1)Combination Gpc-3 with HepPar-1 in human hepatocellular carcinoma, the actual number of disease cases and the number of forecast cases could have a good agreement with an accuracy rate of 93.75%. Therefore Gpc-3 combined with HepPar-1 in the diagnosis of hepatocellular carcinoma can improve the diagnosis of rate and reduce the rate of misdiagnosis. (2)The positive expression of Gpc-3 are relation with pathologic differentiation,HBSAg,AFP. The positive expression of HepPar-1 is relation with lymphatic invasion,HBSAg. (3)Gpc-3 and HepPar-1 in hepatocellular carcinoma has no obvious correlation with each other. Each one can be used as an independent predictor of hepatocellular carcinoma. It will be have a bette rvalue in clinical use if combined the two markers.